Dingchi Bio Completes B++ Financing Round to Advance Veterinary Biologics Industrialization and Domestic Production of Biopharmaceutical Consumables

vbiosci with technologywith technological innovation as the core,Dual-engine growth driven by the animal health sector, focusing on veterinary vaccines and pet pharmaceuticals, and the critical raw materials for biologics sector, centered on culture media and chromatography resins., mutually reinforcing. To date, vbiosci has obtained veterinary vaccines8 Clinical Trial Approvals, including Newcastle Disease and Avian Influenza (ND-AI), Newcastle Disease and Avian Influenza Nasal Vaccine, Newcastle Disease, Avian Influenza and Infectious Bronchitis (ND-AI-IB), Pseudorabies in Swine, Rhinitis Subunit Vaccine, Duck Short Beak Syndrome, Newcastle Disease, Avian Influenza, Infectious Bronchitis and Adenovirus (ND-AI-IB-AdV), and Porcine Circovirus and Mycoplasma Hyopneumoniae Bivalent Vaccine, among which5 New Veterinary Drugs Submitted for Registration, namely, Newcastle disease and avian influenza bivalent vaccine, Newcastle disease, avian influenza and infectious bronchitis trivalent vaccine, Newcastle disease, avian influenza and infectious bronchitis inactivated vaccine (recombinant), pseudorabies virus vaccine, and porcine circovirus type 2 and Mycoplasma hyopneumoniae bivalent vaccine,Ranks among the domestic leaders in the production of embryo-free poultry vaccines and the development of subunit vaccines. Its flagship project, an African swine fever vaccine, pioneers a sequential immunization strategy using “subunit nanoparticles + mRNA.”, preliminary validation has been completed, and the project is progressing in an orderly manner, with significant social and market potential. Based on“IgY Antibody-Based Functional Pet Food ‘Dingban’ Qingmin”Cat food and freeze-dried pellets have also been launched into the market, gaining widespread recognition and benefiting a large number of patients with cat hair allergies. Subsidiary“Yishengke” offers a series of internationally advanced culture media products., including CHO media covering mainstream cell lines, insect cell media for the production of mainstream domestic vaccines and gene therapy drugs, 293 media for protein and gene therapy as well as exosome production, and several serum-free fully suspension culture media for veterinary vaccine production that are first-of-their-kind both domestically and internationally.Yishengke’s Chromatography Media Products Supported the Completion of IND Filings for Multiple Biopharmaceutical Candidates in the First Half of the Year。

For this round of financingResources,Huang Jiangang, Member of the Party Working Committee and Deputy Director of the Administrative Committee of Zhuji Economic and Technological Development ZoneIt was stated that vbiosci, as a star enterprise in Zhuji, has not only achieved remarkable success in the field of biotechnology but also played a positive role in promoting local economic development and industrial upgrading. Adhering to the development philosophy of open cooperation and innovation-driven growth, Zhuji City has continuously optimized its business environment and provided comprehensive support and services to enterprises—including policy incentives, financial assistance, and talent acquisition—to facilitate rapid corporate growth and technological innovation. Meanwhile,Zhuji City is also actively building an industrial ecosystem, continuously empowering enterprises by establishing platforms and hosting events, and welcomes more companies to establish their presence in Zhuji.。

Dr. Ma Ningning, Founder of vbioscistated that since its establishment, vbiosci has adhered to the philosophy of innovation-driven development, dedicating itself to research and development as well as applications in the field of biotechnology.We are deeply grateful to Zhuji Economic and Technological Development Zone for its continuous empowerment of vbiosci., creating a favorable external environment for the development of vbiosci.We also extend our gratitude to all existing shareholders of vbiosci for their support and trust., it is precisely their support and efforts that have laid a solid foundation for the steady development of vbiosci. Remaining true to its original mission, vbiosci will embrace a more open mindset and take firmer steps toward a broader stage, contributing to Chinacontribute to the biotechnology industry.

Zhuji Economic Development ZoneEstablished in 1992,Established as a Provincial High-Tech Industrial Park in 2022. In 2023, the entire region achieved scale-aboveTotal Industrial Output Value: RMB 118.89 Billion, accounting for approximately 74% of the entire Zhuji City, withMore than 900 industrial enterprises above designated size, more than 500 high-tech enterprises, and 13 listed companiesAs the main battlefield for Zhuji’s economic development, the bridgehead for integrating with Hangzhou and connecting to Shanghai, and the testing ground for reform and innovation, Zhuji Economic Development Zone (High-Tech Zone) is positioned with the goal of building a “Smart Manufacturing District · Quality City.” It is making every effort to construct the “Ten Thousand Mu, One Hundred Billion Yuan” new industrial platform for intelligent vision and striving to become a national-level development zone. Established in 2017, Zhuji Jingkai Chuangrong serves as the industrial guidance fund of Zhuji Economic Development Zone.Cumulative investment scale exceeds RMB 10 billion, the fund focuses on the development of innovative enterprises,Focus on the four key sectors: intelligent vision, life and health, new materials, and aerospace.. The fund aims to promote industrial upgrading and innovative development in Zhuji, fostering new drivers of economic growth. The company’s team consistently liaises with various functional departments on behalf of enterprises both before and after investment, addressing challenges encountered at different stages of corporate development, while leveraging Zhejiang’s distinctive advantages.Gaining Recognition from Attracted Enterprises through High-Efficiency Communication and Service。

Since its establishment in 2016, vbiosci has secured continuous investment from renowned institutions, including Tongxieyi, Chenchuang Lihe, Yitang Capital, Yizhuang Pharmaceutical, CMB International, Hillhouse Ventures, Tuojin Capital, Huarui Capital, Ningbo Kexu, Bencao Capital, China Reclamation Fund, Liangshan Fund, Oriental Fortune Capital, Yijing Capital, Suxin Venture Capital, and Zheke Capital. Currently, all business segments of vbiosci are in the final stretch toward large-scale commercialization. The company is committed to creating value for its investors and jointly advancing the localization of raw materials across the upstream and downstream biopharmaceutical supply chain, as well as promoting the industrial technological upgrading of veterinary biological products.